PLOS ONE:一种50岁的细菌,或成癌症治疗的新利器

2016-10-29 生物探索 生物探索

根据美国疾病控制中心,美国大约有4800万人感染食源性疾病,而沙门氏菌是导致疾病的主要原因。沙门氏菌有一个特性——能穿透细胞屏障并在宿主内复制。如今,美国癌症研究中心及密苏里堪萨斯大学的科学家们开发出了一种无毒的沙门氏菌,它可穿透并靶向癌细胞,这项研究成果或将为控制癌症传播带来新的希望。相关结果发表在PLOS ONE杂志上。美国癌症研究中心高级研究员Robert Kazmierczak说,“沙门氏

根据美国疾病控制中心,美国大约有4800万人感染食源性疾病,而沙门氏菌是导致疾病的主要原因。沙门氏菌有一个特性——能穿透细胞屏障并在宿主内复制。如今,美国癌症研究中心及密苏里堪萨斯大学的科学家们开发出了一种无毒的沙门氏菌,它可穿透并靶向癌细胞,这项研究成果或将为控制癌症传播带来新的希望。相关结果发表在PLOS ONE杂志上。

美国癌症研究中心高级研究员Robert Kazmierczak说,“沙门氏菌能自然地浸入肿瘤中,并能进行自我复制,这就使得它成为细菌疗法的一个理想候选者。细菌疗法是使用活细菌来治疗疾病的一种手段,包括治疗癌症等。”

Kazmierczak及其团队开发了一种新的沙门氏菌株——CRC2631,通过基因修饰使沙门氏菌株无毒,还增强了靶向并杀死癌细胞的能力,更重要的是该过程不会伤害到健康的细胞。在研究中,新开发的沙门氏菌株能直接进入到前列腺癌小鼠的循环系统中。



Robert Kazmierczak

“我们发现小鼠的耐受性和治疗反应良好,与对照组相比,试验小鼠的前列腺肿瘤缩小了20%左右。”Kazmierczak说,“沙门氏菌最显著的能力在于它能靶向肿瘤,并在肿瘤内部进行传播。我们正是利用了它的这种能力,通过携带或生产有效的化疗药物,并将这些药物带入到整个肿瘤当中。这种方法的宗旨是开发一种细菌载体,这种载体能彻底破坏肿瘤,并且要减少患者的副作用。”

CRC2631最初来源于专门存储沙门氏菌的菌库,库中的菌株由遗传学家 Milisav Demerec搜集,并在常温下储存了50年。菌库中包含了上2万种不同的沙门氏菌样本,其中一半保藏在癌症研究中心,这里的研究人员主要专注于癌症的早期检测、靶向治疗以及有效地化疗。

研究人员表示, “只有那些与我们目标一致的人才能区分出CRC2631与其他沙门氏菌,使用CRC2631菌株也是我们的研究得以成功的必不可少因素。”


原始出处

Robert A. Kazmierczak , Bettina Gentry, Tyler Mumm, Heide Schatten, Abraham Eisenstark.Salmonella Bacterial Monotherapy Reduces Autochthonous Prostate Tumor Burden in the TRAMP Mouse Model.PLOS ONE.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789847, encodeId=67141e89847a0, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Feb 12 04:17:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844196, encodeId=a63a184419637, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Jan 07 22:17:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152139, encodeId=c2a015213957, content=这个研究有点意思。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Sun Oct 30 09:44:53 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151980, encodeId=c6a215198084, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a3891971397, createdName=1e16063cm16(暂无匿称), createdTime=Sat Oct 29 14:52:18 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789847, encodeId=67141e89847a0, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Feb 12 04:17:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844196, encodeId=a63a184419637, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Jan 07 22:17:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152139, encodeId=c2a015213957, content=这个研究有点意思。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Sun Oct 30 09:44:53 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151980, encodeId=c6a215198084, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a3891971397, createdName=1e16063cm16(暂无匿称), createdTime=Sat Oct 29 14:52:18 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789847, encodeId=67141e89847a0, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Feb 12 04:17:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844196, encodeId=a63a184419637, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Jan 07 22:17:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152139, encodeId=c2a015213957, content=这个研究有点意思。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Sun Oct 30 09:44:53 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151980, encodeId=c6a215198084, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a3891971397, createdName=1e16063cm16(暂无匿称), createdTime=Sat Oct 29 14:52:18 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
    2016-10-30 studylzc

    这个研究有点意思。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1789847, encodeId=67141e89847a0, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Feb 12 04:17:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844196, encodeId=a63a184419637, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Jan 07 22:17:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152139, encodeId=c2a015213957, content=这个研究有点意思。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Sun Oct 30 09:44:53 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151980, encodeId=c6a215198084, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a3891971397, createdName=1e16063cm16(暂无匿称), createdTime=Sat Oct 29 14:52:18 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
    2016-10-29 1e16063cm16(暂无匿称)

    学习中

    0